A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Latest Information Update: 23 Jul 2025
At a glance
- Drugs HMR-59 (Primary) ; Prednisone; Triamcinolone
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms PARASOL
- Sponsors Janssen; Janssen Research & Development
Most Recent Events
- 23 May 2025 Planned End Date changed from 19 May 2026 to 8 Mar 2026.
- 27 Feb 2025 Planned End Date changed from 26 Feb 2026 to 19 May 2026.
- 10 Jan 2025 Planned End Date changed from 2 Mar 2026 to 26 Feb 2026.